Future investigations should focus on profiling IL‐33 on sputum and/or airway biopsies of patients with COPD and asthma, with an emphasis on distinguishing IL‐33 levels across different pheno‐endotypes. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.